1/5/2022 6:02:05 AM
IDEAYA Biosciences Announces Acquisition Of Proprietary INQUIRE Chemical Library
1/4/2022 6:02:07 AM
IDEAYA Biosciences Appoints Frank McCormick As Chair Of Scientific Advisory Board
12/7/2021 7:12:35 AM
IDEAYA Reports Data From Phase 2 Expansion Dose Of Darovasertib And Crizotinib Synthetic Lethal Combination In MUM
11/17/2021 4:37:08 PM
Wedbush Reiterates IDEAYA Biosciences (IDYA) At Outperform With $31 Price Target
11/15/2021 6:07:29 AM
IDEAYA Biosciences Q3 Net Loss Widens To $11.6 Mln From $10.9 Mln Last Year
10/18/2021 6:02:35 AM
IDEAYA Biosciences Appoints Michael White As Chief Scientific Officer
8/10/2021 6:05:29 AM
IDEAYA Biosciences Q2 Loss Per Share $0.33 Vs Loss $0.28 Last Quarter
7/7/2021 9:32:23 PM
IDEAYA Biosciences Prices Public Offering Of 4.64 Mln Shares At $17.25/shr
7/6/2021 4:04:45 PM
IDEAYA Announces Proposed Public Offering Of Common Stock
6/28/2021 6:10:50 AM
IDEAYA Unveils IDE397 Phase 1 Clinical Pharmacodynamic Data, Phase 2 Initiation Of Darovasertib, Crizotinib Combination
4/16/2021 6:04:05 AM
IDEAYA Reports Darovasertib Monotherapy OS Data; Observes Early Partial Responses In Binimetinib Combination In MUM
4/15/2021 6:01:57 AM
IDEAYA Announces Doses First Patient Of MAT2A Inhibitor IDE397 In Phase 1 Clinical Trial Of MTAP-Deletion Solid Tumors
3/23/2021 6:08:11 AM
IDEAYA Announces Dose Expansion Of Phase 1/2 Study Of Combination Of IDE196 And Binimetinib In Metastatic Uveal Melanoma
3/23/2021 6:07:55 AM
IDEAYA Biosciences Q4 Net Loss $5.1 Mln Vs. Net Loss $10.8 Mln Last Year
3/11/2021 6:07:57 AM
IDEAYA Announces Presentations At AACR For Synthetic Lethality Programs IDE397 And PARG, And Kinase Inhibitor IDE196